Assignee
SANA BIOTECHNOLOGY INC
US·6 granted patents·53 pending applications·16 citations·filing 2020–2025
Top patents by PatentIndex Score
59 records- 0189US11535869B2CD8-specific antibody constructs and compositions thereofSANA BIOTECHNOLOGY INC·Filed 2022·Granted Dec 27, 2022·13 cites·30 claims
- 0288US11802157B2Methods and compositions for modulating CAR-T activitySANA BIOTECHNOLOGY INC·Filed 2022·Granted Oct 31, 2023·1 cites·27 claims
- 0380US11987628B2Methods and compositions for modulating CAR-T activitySANA BIOTECHNOLOGY INC·Filed 2023·Granted May 21, 2024·0 cites·30 claims
- 0480US2025019433A1Methods and compositions for modulating car-t activitySANA BIOTECHNOLOGY INC·Filed 2024·Application pending·0 cites
- 0575US11965022B2Methods and compositions for modulating CAR-T activitySANA BIOTECHNOLOGY INC·Filed 2021·Granted Apr 23, 2024·0 cites·20 claims
- 0666US2025177447A1Gprc5d-specific antibody constructs and compositions thereofSANA BIOTECHNOLOGY INC·Filed 2024·Application pending·0 cites
- 0766US2026027145A1Methods of transduction using a viral vector and inhibitors of antiviral restriction factorsSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 0865US2025144235A1Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and usesSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 0965US2025222027A1Cytokine receptor agonist and viral vector combination therapiesSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 1064US2025223564A1Hypoimmune beta cells differentiated from pluripotent stem cells and related uses and methodsSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 1164US2025059560A1Methods and systems of particle productionSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 1264US2025082777A1Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and usesSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 1363US2026048086A1Methods of dosing and administration of engineered islet cellsSANA BIOTECHNOLOGY INC·Filed 2025·Application pending·0 cites
- 1463US2025333476A1Engineered cd47 proteins and uses thereofSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 1562US2026055146A1Delivery of heterologous proteinsSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 1662US2025333469A1Use of cd8-targeted viral vectorsSANA BIOTECHNOLOGY INC·Filed 2025·Application pending·0 cites
- 1762US2023293581A1Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositionsSANA BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
- 1862US2025313861A1Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methodsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 1962US2025129346A1Engineering cells for cell-based therapies, and associated compositions and methodsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 2062US2024010988A1Genetically modified primary cells for allogeneic cell therapySANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 2162US2023257773A1Cd8-specific antibody constructs and compositions thereofSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 2262US2025230511A1Methods and reagents for amplifying viral vector nucleic acid productsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 2362US2022049226A1Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositionsSANA BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
- 2462US2025281536A1Cd4-specific antibody constructs and compositions and uses thereofSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 2561US2025127820A1Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactionsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 2661US2025302953A1Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cellsSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 2761US2024425820A1Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactionsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 2860US2024268375A1Cryogenic cassettes and associated systems, devices, and methodsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 2960US2024254168A1LIPID PARTICLES CONTAINING A TRUNCATED BABOON ENDOGENOUS RETROVIRUS (BaEV) ENVELOPE GLYCOPROTEIN AND RELATED METHODS AND USESSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 3059US2023383261A1Hepatocyte-like cellsSANA BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
- 3159US2024226164A1Hypoimmunogenic cells comprising engineered hla-e or hla-gSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 3259US2025302876A1Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methodsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 3358US2024358761A1Genetically modified cells for allogeneic cell therapySANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 3458US2024316198A1Altered expression of y chromosome-linked antigens in hypoimmunogenic cellsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 3557US2022241328A1Use of cd8-targeted viral vectorsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 3657US2024408192A1Modified paramyxoviridae attachment glycoproteinsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 3757US2025152709A1Cd3-targeted lentiviral vectors and uses thereofSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 3857US2024252642A1Hypoimmunogenic rhd negative primary t cellsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 3957US2024278248A1Cryogenic storage racks and associated systems, devices, and methodsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 4057US2025059239A1Modified paramyxoviridae fusion glycoproteinsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 4156US2025101382A1Genetically modified cells and compositions and uses thereofSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 4256US2026098062A1Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereofSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 4356US2023272429A1Modification of blood type antigensSANA BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
- 4454US2024344083A1Use of cd4-targeted viral vectorsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 4554US2025320290A1METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPalpha BLOCKADE AGENTSANA BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
- 4654US2023303665A1Modified anti-viral binding agentsSANA BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
- 4753US2025122529A1Polycistronic vectors for cell-based therapiesSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 4852US2023190871A1Methods and compositions for treatment of viral infectionsSANA BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
- 4952US2023293593A1Hypoimmunogenic neural cells for the treatment of neurological disorders and conditionsSANA BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
- 5052US2021353543A1Targeted lipid particles and compositions and uses thereofSANA BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 59 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when SANA BIOTECHNOLOGY INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →